Xiamen Amoytop Biotech (SHA:688278) on Tuesday launched a convertible bond issue of 1.53 billion yuan, according to a Tuesday filing with the Shanghai bourse.
Guojin Securities serves as lead underwriter, with CICC as joint lead underwriter. The bond issue carries a 30% maximum underwriter liability cap of 460.0 million yuan.
Shares of the drugmaker were down 4% in recent trade.